nodes	percent_of_prediction	percent_of_DWPC	metapath
Octreotide—MPO—Carboplatin—esophageal cancer	0.374	0.539	CbGbCtD
Octreotide—MPO—Cisplatin—esophageal cancer	0.319	0.461	CbGbCtD
Octreotide—Desmopressin—PTGS1—esophageal cancer	0.000872	0.636	CrCbGaD
Octreotide—Phlebitis—Capecitabine—esophageal cancer	0.000572	0.00353	CcSEcCtD
Octreotide—Sleep disorder—Capecitabine—esophageal cancer	0.00057	0.00352	CcSEcCtD
Octreotide—Thrombophlebitis—Capecitabine—esophageal cancer	0.00057	0.00352	CcSEcCtD
Octreotide—Diabetes mellitus—Capecitabine—esophageal cancer	0.000567	0.0035	CcSEcCtD
Octreotide—Blood alkaline phosphatase increased—Capecitabine—esophageal cancer	0.000567	0.0035	CcSEcCtD
Octreotide—Pancreatitis—Cisplatin—esophageal cancer	0.000567	0.0035	CcSEcCtD
Octreotide—Sweating increased—Cisplatin—esophageal cancer	0.000563	0.00348	CcSEcCtD
Octreotide—Polyuria—Capecitabine—esophageal cancer	0.000562	0.00347	CcSEcCtD
Octreotide—Gastroenteritis—Capecitabine—esophageal cancer	0.000556	0.00343	CcSEcCtD
Octreotide—Hyperbilirubinaemia—Methotrexate—esophageal cancer	0.000556	0.00343	CcSEcCtD
Octreotide—Abdominal discomfort—Cisplatin—esophageal cancer	0.000554	0.00342	CcSEcCtD
Octreotide—Deafness—Capecitabine—esophageal cancer	0.000551	0.0034	CcSEcCtD
Octreotide—Herpes simplex—Methotrexate—esophageal cancer	0.000549	0.00339	CcSEcCtD
Octreotide—Hot flush—Capecitabine—esophageal cancer	0.000527	0.00325	CcSEcCtD
Octreotide—Amnesia—Capecitabine—esophageal cancer	0.000525	0.00324	CcSEcCtD
Octreotide—Menopausal symptoms—Capecitabine—esophageal cancer	0.000523	0.00323	CcSEcCtD
Octreotide—Arthritis—Capecitabine—esophageal cancer	0.000507	0.00313	CcSEcCtD
Octreotide—Vaginal inflammation—Methotrexate—esophageal cancer	0.000506	0.00312	CcSEcCtD
Octreotide—Neuropathy peripheral—Cisplatin—esophageal cancer	0.000505	0.00312	CcSEcCtD
Octreotide—Conjunctivitis—Cisplatin—esophageal cancer	0.000501	0.00309	CcSEcCtD
Octreotide—Desmopressin—PTGS2—esophageal cancer	0.000498	0.364	CrCbGaD
Octreotide—Cystitis noninfective—Methotrexate—esophageal cancer	0.000494	0.00305	CcSEcCtD
Octreotide—Pain in extremity—Capecitabine—esophageal cancer	0.000493	0.00304	CcSEcCtD
Octreotide—Osteoarthritis—Capecitabine—esophageal cancer	0.000493	0.00304	CcSEcCtD
Octreotide—Gastrointestinal haemorrhage—Capecitabine—esophageal cancer	0.000493	0.00304	CcSEcCtD
Octreotide—Cystitis—Methotrexate—esophageal cancer	0.000488	0.00301	CcSEcCtD
Octreotide—Hepatobiliary disease—Cisplatin—esophageal cancer	0.000487	0.00301	CcSEcCtD
Octreotide—Vaginal infection—Methotrexate—esophageal cancer	0.000477	0.00295	CcSEcCtD
Octreotide—Bradycardia—Cisplatin—esophageal cancer	0.000471	0.00291	CcSEcCtD
Octreotide—Irritability—Capecitabine—esophageal cancer	0.000471	0.0029	CcSEcCtD
Octreotide—Dehydration—Capecitabine—esophageal cancer	0.000459	0.00283	CcSEcCtD
Octreotide—Mouth ulceration—Methotrexate—esophageal cancer	0.000457	0.00282	CcSEcCtD
Octreotide—Bladder pain—Methotrexate—esophageal cancer	0.000457	0.00282	CcSEcCtD
Octreotide—Urine output increased—Methotrexate—esophageal cancer	0.000457	0.00282	CcSEcCtD
Octreotide—Gynaecomastia—Methotrexate—esophageal cancer	0.000452	0.00279	CcSEcCtD
Octreotide—Dry skin—Capecitabine—esophageal cancer	0.000452	0.00279	CcSEcCtD
Octreotide—Abdominal pain upper—Capecitabine—esophageal cancer	0.00045	0.00278	CcSEcCtD
Octreotide—Visual impairment—Cisplatin—esophageal cancer	0.000446	0.00275	CcSEcCtD
Octreotide—Nasopharyngitis—Capecitabine—esophageal cancer	0.000441	0.00272	CcSEcCtD
Octreotide—Gastritis—Capecitabine—esophageal cancer	0.000436	0.00269	CcSEcCtD
Octreotide—Muscular weakness—Capecitabine—esophageal cancer	0.000435	0.00268	CcSEcCtD
Octreotide—Tinnitus—Cisplatin—esophageal cancer	0.000431	0.00266	CcSEcCtD
Octreotide—Flushing—Cisplatin—esophageal cancer	0.000429	0.00265	CcSEcCtD
Octreotide—Cardiac disorder—Cisplatin—esophageal cancer	0.000429	0.00265	CcSEcCtD
Octreotide—Abdominal distension—Capecitabine—esophageal cancer	0.000429	0.00265	CcSEcCtD
Octreotide—Influenza—Capecitabine—esophageal cancer	0.000426	0.00263	CcSEcCtD
Octreotide—Asthma—Capecitabine—esophageal cancer	0.000426	0.00263	CcSEcCtD
Octreotide—Thrombophlebitis—Methotrexate—esophageal cancer	0.000424	0.00262	CcSEcCtD
Octreotide—Diabetes mellitus—Methotrexate—esophageal cancer	0.000422	0.0026	CcSEcCtD
Octreotide—Bronchospasm—Capecitabine—esophageal cancer	0.000419	0.00259	CcSEcCtD
Octreotide—Polyuria—Methotrexate—esophageal cancer	0.000418	0.00258	CcSEcCtD
Octreotide—Immune system disorder—Cisplatin—esophageal cancer	0.000418	0.00258	CcSEcCtD
Octreotide—Sweating increased—Capecitabine—esophageal cancer	0.000415	0.00256	CcSEcCtD
Octreotide—Arrhythmia—Cisplatin—esophageal cancer	0.000413	0.00255	CcSEcCtD
Octreotide—Bronchitis—Capecitabine—esophageal cancer	0.00041	0.00253	CcSEcCtD
Octreotide—Alopecia—Cisplatin—esophageal cancer	0.000409	0.00252	CcSEcCtD
Octreotide—Abdominal discomfort—Capecitabine—esophageal cancer	0.000409	0.00252	CcSEcCtD
Octreotide—Erythema—Cisplatin—esophageal cancer	0.000403	0.00249	CcSEcCtD
Octreotide—Malnutrition—Cisplatin—esophageal cancer	0.000403	0.00249	CcSEcCtD
Octreotide—Dysuria—Capecitabine—esophageal cancer	0.000398	0.00246	CcSEcCtD
Octreotide—Flatulence—Cisplatin—esophageal cancer	0.000397	0.00245	CcSEcCtD
Octreotide—Upper respiratory tract infection—Capecitabine—esophageal cancer	0.000396	0.00244	CcSEcCtD
Octreotide—Weight increased—Capecitabine—esophageal cancer	0.000388	0.00239	CcSEcCtD
Octreotide—Visual disturbance—Methotrexate—esophageal cancer	0.000387	0.00239	CcSEcCtD
Octreotide—Muscle spasms—Cisplatin—esophageal cancer	0.000387	0.00239	CcSEcCtD
Octreotide—Weight decreased—Capecitabine—esophageal cancer	0.000386	0.00238	CcSEcCtD
Octreotide—Hyperglycaemia—Capecitabine—esophageal cancer	0.000384	0.00237	CcSEcCtD
Octreotide—Pneumonia—Capecitabine—esophageal cancer	0.000382	0.00236	CcSEcCtD
Octreotide—Vision blurred—Cisplatin—esophageal cancer	0.00038	0.00234	CcSEcCtD
Octreotide—Anaphylactoid reaction—Methotrexate—esophageal cancer	0.000379	0.00234	CcSEcCtD
Octreotide—Depression—Capecitabine—esophageal cancer	0.000379	0.00234	CcSEcCtD
Octreotide—Tremor—Cisplatin—esophageal cancer	0.000377	0.00233	CcSEcCtD
Octreotide—Ill-defined disorder—Cisplatin—esophageal cancer	0.000374	0.00231	CcSEcCtD
Octreotide—Neuropathy peripheral—Capecitabine—esophageal cancer	0.000372	0.0023	CcSEcCtD
Octreotide—Anaemia—Cisplatin—esophageal cancer	0.000372	0.0023	CcSEcCtD
Octreotide—Jaundice—Capecitabine—esophageal cancer	0.00037	0.00229	CcSEcCtD
Octreotide—Urinary tract infection—Capecitabine—esophageal cancer	0.000369	0.00228	CcSEcCtD
Octreotide—Conjunctivitis—Capecitabine—esophageal cancer	0.000369	0.00228	CcSEcCtD
Octreotide—Osteoarthritis—Methotrexate—esophageal cancer	0.000367	0.00227	CcSEcCtD
Octreotide—Malaise—Cisplatin—esophageal cancer	0.000363	0.00224	CcSEcCtD
Octreotide—Haematuria—Capecitabine—esophageal cancer	0.000362	0.00224	CcSEcCtD
Octreotide—Hepatobiliary disease—Capecitabine—esophageal cancer	0.000359	0.00222	CcSEcCtD
Octreotide—Epistaxis—Capecitabine—esophageal cancer	0.000358	0.00221	CcSEcCtD
Octreotide—Irritability—Methotrexate—esophageal cancer	0.00035	0.00216	CcSEcCtD
Octreotide—Convulsion—Cisplatin—esophageal cancer	0.000349	0.00215	CcSEcCtD
Octreotide—Bradycardia—Capecitabine—esophageal cancer	0.000347	0.00214	CcSEcCtD
Octreotide—Myalgia—Cisplatin—esophageal cancer	0.000343	0.00212	CcSEcCtD
Octreotide—Rhinitis—Capecitabine—esophageal cancer	0.000342	0.00211	CcSEcCtD
Octreotide—Anxiety—Cisplatin—esophageal cancer	0.000342	0.00211	CcSEcCtD
Octreotide—Hepatitis—Capecitabine—esophageal cancer	0.000341	0.00211	CcSEcCtD
Octreotide—Unspecified disorder of skin and subcutaneous tissue—Cisplatin—esophageal cancer	0.000341	0.0021	CcSEcCtD
Octreotide—Hypoaesthesia—Capecitabine—esophageal cancer	0.000339	0.00209	CcSEcCtD
Octreotide—Discomfort—Cisplatin—esophageal cancer	0.000339	0.00209	CcSEcCtD
Octreotide—Pharyngitis—Capecitabine—esophageal cancer	0.000339	0.00209	CcSEcCtD
Octreotide—Oedema peripheral—Capecitabine—esophageal cancer	0.000336	0.00207	CcSEcCtD
Octreotide—Anaphylactic shock—Cisplatin—esophageal cancer	0.000329	0.00203	CcSEcCtD
Octreotide—Oedema—Cisplatin—esophageal cancer	0.000329	0.00203	CcSEcCtD
Octreotide—Visual impairment—Capecitabine—esophageal cancer	0.000329	0.00203	CcSEcCtD
Octreotide—Infection—Cisplatin—esophageal cancer	0.000327	0.00202	CcSEcCtD
Octreotide—Nervous system disorder—Cisplatin—esophageal cancer	0.000322	0.00199	CcSEcCtD
Octreotide—Thrombocytopenia—Cisplatin—esophageal cancer	0.000322	0.00199	CcSEcCtD
Octreotide—Tachycardia—Cisplatin—esophageal cancer	0.000321	0.00198	CcSEcCtD
Octreotide—Skin disorder—Cisplatin—esophageal cancer	0.000319	0.00197	CcSEcCtD
Octreotide—Tinnitus—Capecitabine—esophageal cancer	0.000318	0.00196	CcSEcCtD
Octreotide—Hyperhidrosis—Cisplatin—esophageal cancer	0.000318	0.00196	CcSEcCtD
Octreotide—Asthma—Methotrexate—esophageal cancer	0.000317	0.00196	CcSEcCtD
Octreotide—Flushing—Capecitabine—esophageal cancer	0.000317	0.00195	CcSEcCtD
Octreotide—Cardiac disorder—Capecitabine—esophageal cancer	0.000317	0.00195	CcSEcCtD
Octreotide—Anorexia—Cisplatin—esophageal cancer	0.000313	0.00193	CcSEcCtD
Octreotide—Pancreatitis—Methotrexate—esophageal cancer	0.000311	0.00192	CcSEcCtD
Octreotide—Immune system disorder—Capecitabine—esophageal cancer	0.000308	0.0019	CcSEcCtD
Octreotide—Arrhythmia—Capecitabine—esophageal cancer	0.000305	0.00188	CcSEcCtD
Octreotide—Abdominal discomfort—Methotrexate—esophageal cancer	0.000304	0.00188	CcSEcCtD
Octreotide—Alopecia—Capecitabine—esophageal cancer	0.000301	0.00186	CcSEcCtD
Octreotide—SSTR3—Signaling Pathways—ADCYAP1—esophageal cancer	0.0003	0.00209	CbGpPWpGaD
Octreotide—Musculoskeletal discomfort—Cisplatin—esophageal cancer	0.0003	0.00185	CcSEcCtD
Octreotide—SSTR3—Signaling by GPCR—PDE4D—esophageal cancer	0.000299	0.00209	CbGpPWpGaD
Octreotide—SSTR4—Signaling by GPCR—SST—esophageal cancer	0.000299	0.00209	CbGpPWpGaD
Octreotide—Mental disorder—Capecitabine—esophageal cancer	0.000299	0.00184	CcSEcCtD
Octreotide—Erythema—Capecitabine—esophageal cancer	0.000297	0.00183	CcSEcCtD
Octreotide—Malnutrition—Capecitabine—esophageal cancer	0.000297	0.00183	CcSEcCtD
Octreotide—Dysuria—Methotrexate—esophageal cancer	0.000297	0.00183	CcSEcCtD
Octreotide—Paraesthesia—Cisplatin—esophageal cancer	0.000295	0.00182	CcSEcCtD
Octreotide—Upper respiratory tract infection—Methotrexate—esophageal cancer	0.000295	0.00182	CcSEcCtD
Octreotide—Dyspnoea—Cisplatin—esophageal cancer	0.000293	0.00181	CcSEcCtD
Octreotide—Flatulence—Capecitabine—esophageal cancer	0.000293	0.00181	CcSEcCtD
Octreotide—MPO—C-MYB transcription factor network—EP300—esophageal cancer	0.000291	0.00203	CbGpPWpGaD
Octreotide—SSTR4—Signaling by GPCR—GHRL—esophageal cancer	0.000291	0.00203	CbGpPWpGaD
Octreotide—SSTR4—Signaling Pathways—PFN1—esophageal cancer	0.00029	0.00203	CbGpPWpGaD
Octreotide—SSTR1—Signaling Pathways—ADCYAP1—esophageal cancer	0.000287	0.00201	CbGpPWpGaD
Octreotide—Back pain—Capecitabine—esophageal cancer	0.000287	0.00177	CcSEcCtD
Octreotide—SSTR1—Signaling by GPCR—PDE4D—esophageal cancer	0.000287	0.002	CbGpPWpGaD
Octreotide—SSTR5—Signaling Pathways—KMT2D—esophageal cancer	0.000286	0.002	CbGpPWpGaD
Octreotide—Decreased appetite—Cisplatin—esophageal cancer	0.000286	0.00176	CcSEcCtD
Octreotide—Muscle spasms—Capecitabine—esophageal cancer	0.000285	0.00176	CcSEcCtD
Octreotide—Pneumonia—Methotrexate—esophageal cancer	0.000285	0.00176	CcSEcCtD
Octreotide—SSTR3—Signaling by GPCR—GNG7—esophageal cancer	0.000284	0.00199	CbGpPWpGaD
Octreotide—Gastrointestinal disorder—Cisplatin—esophageal cancer	0.000284	0.00175	CcSEcCtD
Octreotide—Drowsiness—Methotrexate—esophageal cancer	0.000283	0.00175	CcSEcCtD
Octreotide—SSTR2—GPCR downstream signaling—AKAP13—esophageal cancer	0.000282	0.00197	CbGpPWpGaD
Octreotide—Depression—Methotrexate—esophageal cancer	0.000282	0.00174	CcSEcCtD
Octreotide—Pain—Cisplatin—esophageal cancer	0.000281	0.00174	CcSEcCtD
Octreotide—SSTR5—GPCR downstream signaling—PDE4D—esophageal cancer	0.00028	0.00195	CbGpPWpGaD
Octreotide—Vision blurred—Capecitabine—esophageal cancer	0.00028	0.00173	CcSEcCtD
Octreotide—Tremor—Capecitabine—esophageal cancer	0.000278	0.00172	CcSEcCtD
Octreotide—SSTR5—Signaling by GPCR—AKAP13—esophageal cancer	0.000278	0.00194	CbGpPWpGaD
Octreotide—SSTR3—GPCR downstream signaling—CXCL2—esophageal cancer	0.000276	0.00193	CbGpPWpGaD
Octreotide—Ill-defined disorder—Capecitabine—esophageal cancer	0.000276	0.0017	CcSEcCtD
Octreotide—Conjunctivitis—Methotrexate—esophageal cancer	0.000275	0.0017	CcSEcCtD
Octreotide—Anaemia—Capecitabine—esophageal cancer	0.000274	0.00169	CcSEcCtD
Octreotide—SSTR3—Signaling Pathways—WWOX—esophageal cancer	0.000274	0.00191	CbGpPWpGaD
Octreotide—SSTR1—Signaling by GPCR—GNG7—esophageal cancer	0.000273	0.0019	CbGpPWpGaD
Octreotide—Feeling abnormal—Cisplatin—esophageal cancer	0.000271	0.00167	CcSEcCtD
Octreotide—Haematuria—Methotrexate—esophageal cancer	0.00027	0.00166	CcSEcCtD
Octreotide—Malaise—Capecitabine—esophageal cancer	0.000268	0.00165	CcSEcCtD
Octreotide—Hepatobiliary disease—Methotrexate—esophageal cancer	0.000268	0.00165	CcSEcCtD
Octreotide—Epistaxis—Methotrexate—esophageal cancer	0.000267	0.00165	CcSEcCtD
Octreotide—Vertigo—Capecitabine—esophageal cancer	0.000267	0.00165	CcSEcCtD
Octreotide—Syncope—Capecitabine—esophageal cancer	0.000266	0.00164	CcSEcCtD
Octreotide—SSTR5—GPCR downstream signaling—GNG7—esophageal cancer	0.000266	0.00186	CbGpPWpGaD
Octreotide—SSTR2—SIDS Susceptibility Pathways—EP300—esophageal cancer	0.000265	0.00185	CbGpPWpGaD
Octreotide—SSTR1—GPCR downstream signaling—CXCL2—esophageal cancer	0.000265	0.00185	CbGpPWpGaD
Octreotide—SSTR2—Signaling Pathways—KMT2D—esophageal cancer	0.000264	0.00184	CbGpPWpGaD
Octreotide—SSTR1—Signaling Pathways—WWOX—esophageal cancer	0.000263	0.00183	CbGpPWpGaD
Octreotide—Palpitations—Capecitabine—esophageal cancer	0.000262	0.00162	CcSEcCtD
Octreotide—Loss of consciousness—Capecitabine—esophageal cancer	0.000261	0.00161	CcSEcCtD
Octreotide—SSTR3—Signaling Pathways—FKBP1A—esophageal cancer	0.000261	0.00182	CbGpPWpGaD
Octreotide—SSTR4—Signaling Pathways—ELMO1—esophageal cancer	0.000261	0.00182	CbGpPWpGaD
Octreotide—Body temperature increased—Cisplatin—esophageal cancer	0.00026	0.0016	CcSEcCtD
Octreotide—Cough—Capecitabine—esophageal cancer	0.000259	0.0016	CcSEcCtD
Octreotide—SSTR2—GPCR downstream signaling—PDE4D—esophageal cancer	0.000258	0.0018	CbGpPWpGaD
Octreotide—SSTR2—Signaling by GPCR—AKAP13—esophageal cancer	0.000257	0.00179	CbGpPWpGaD
Octreotide—SSTR3—GPCR downstream signaling—ANXA1—esophageal cancer	0.000257	0.00179	CbGpPWpGaD
Octreotide—Hypertension—Capecitabine—esophageal cancer	0.000256	0.00158	CcSEcCtD
Octreotide—SSTR5—Signaling Pathways—ADCYAP1—esophageal cancer	0.000255	0.00178	CbGpPWpGaD
Octreotide—SSTR4—Signaling Pathways—AKAP13—esophageal cancer	0.000255	0.00178	CbGpPWpGaD
Octreotide—SSTR3—Signaling Pathways—WIF1—esophageal cancer	0.000255	0.00178	CbGpPWpGaD
Octreotide—SSTR5—Signaling by GPCR—PDE4D—esophageal cancer	0.000254	0.00177	CbGpPWpGaD
Octreotide—MPO—C-MYB transcription factor network—MYC—esophageal cancer	0.000254	0.00177	CbGpPWpGaD
Octreotide—Hepatitis—Methotrexate—esophageal cancer	0.000254	0.00157	CcSEcCtD
Octreotide—MPO—Folate Metabolism—TP53—esophageal cancer	0.000253	0.00177	CbGpPWpGaD
Octreotide—Myalgia—Capecitabine—esophageal cancer	0.000253	0.00156	CcSEcCtD
Octreotide—Chest pain—Capecitabine—esophageal cancer	0.000253	0.00156	CcSEcCtD
Octreotide—Arthralgia—Capecitabine—esophageal cancer	0.000253	0.00156	CcSEcCtD
Octreotide—Pharyngitis—Methotrexate—esophageal cancer	0.000252	0.00156	CcSEcCtD
Octreotide—Anxiety—Capecitabine—esophageal cancer	0.000252	0.00156	CcSEcCtD
Octreotide—Unspecified disorder of skin and subcutaneous tissue—Capecitabine—esophageal cancer	0.000251	0.00155	CcSEcCtD
Octreotide—SSTR3—Signaling by GPCR—CXCL2—esophageal cancer	0.000251	0.00175	CbGpPWpGaD
Octreotide—SSTR1—Signaling Pathways—FKBP1A—esophageal cancer	0.00025	0.00175	CbGpPWpGaD
Octreotide—Discomfort—Capecitabine—esophageal cancer	0.00025	0.00154	CcSEcCtD
Octreotide—SSTR3—GPCR downstream signaling—SST—esophageal cancer	0.00025	0.00174	CbGpPWpGaD
Octreotide—Dry mouth—Capecitabine—esophageal cancer	0.000247	0.00153	CcSEcCtD
Octreotide—SSTR1—GPCR downstream signaling—ANXA1—esophageal cancer	0.000246	0.00172	CbGpPWpGaD
Octreotide—SSTR2—GPCR downstream signaling—GNG7—esophageal cancer	0.000246	0.00172	CbGpPWpGaD
Octreotide—Visual impairment—Methotrexate—esophageal cancer	0.000245	0.00151	CcSEcCtD
Octreotide—SSTR1—Signaling Pathways—WIF1—esophageal cancer	0.000244	0.00171	CbGpPWpGaD
Octreotide—SSTR3—GPCR downstream signaling—GHRL—esophageal cancer	0.000243	0.0017	CbGpPWpGaD
Octreotide—Oedema—Capecitabine—esophageal cancer	0.000242	0.0015	CcSEcCtD
Octreotide—Hypersensitivity—Cisplatin—esophageal cancer	0.000242	0.0015	CcSEcCtD
Octreotide—SSTR5—Signaling by GPCR—GNG7—esophageal cancer	0.000242	0.00169	CbGpPWpGaD
Octreotide—Infection—Capecitabine—esophageal cancer	0.000241	0.00149	CcSEcCtD
Octreotide—SSTR1—Signaling by GPCR—CXCL2—esophageal cancer	0.00024	0.00168	CbGpPWpGaD
Octreotide—SSTR1—GPCR downstream signaling—SST—esophageal cancer	0.000239	0.00167	CbGpPWpGaD
Octreotide—Shock—Capecitabine—esophageal cancer	0.000238	0.00147	CcSEcCtD
Octreotide—Nervous system disorder—Capecitabine—esophageal cancer	0.000238	0.00147	CcSEcCtD
Octreotide—Thrombocytopenia—Capecitabine—esophageal cancer	0.000237	0.00146	CcSEcCtD
Octreotide—Tinnitus—Methotrexate—esophageal cancer	0.000237	0.00146	CcSEcCtD
Octreotide—Tachycardia—Capecitabine—esophageal cancer	0.000237	0.00146	CcSEcCtD
Octreotide—Asthenia—Cisplatin—esophageal cancer	0.000236	0.00146	CcSEcCtD
Octreotide—Cardiac disorder—Methotrexate—esophageal cancer	0.000236	0.00145	CcSEcCtD
Octreotide—Skin disorder—Capecitabine—esophageal cancer	0.000235	0.00145	CcSEcCtD
Octreotide—SSTR2—Signaling Pathways—ADCYAP1—esophageal cancer	0.000235	0.00164	CbGpPWpGaD
Octreotide—SSTR3—Signaling Pathways—CSNK1A1—esophageal cancer	0.000235	0.00164	CbGpPWpGaD
Octreotide—SSTR4—Signaling Pathways—HIST1H2BM—esophageal cancer	0.000235	0.00164	CbGpPWpGaD
Octreotide—SSTR2—Signaling by GPCR—PDE4D—esophageal cancer	0.000235	0.00164	CbGpPWpGaD
Octreotide—SSTR5—GPCR downstream signaling—CXCL2—esophageal cancer	0.000235	0.00164	CbGpPWpGaD
Octreotide—Hyperhidrosis—Capecitabine—esophageal cancer	0.000234	0.00145	CcSEcCtD
Octreotide—SSTR1—GPCR downstream signaling—GHRL—esophageal cancer	0.000233	0.00163	CbGpPWpGaD
Octreotide—SSTR5—Signaling Pathways—WWOX—esophageal cancer	0.000233	0.00163	CbGpPWpGaD
Octreotide—SSTR4—Signaling Pathways—PDE4D—esophageal cancer	0.000233	0.00163	CbGpPWpGaD
Octreotide—SSTR3—Signaling by GPCR—ANXA1—esophageal cancer	0.000233	0.00163	CbGpPWpGaD
Octreotide—Anorexia—Capecitabine—esophageal cancer	0.000231	0.00143	CcSEcCtD
Octreotide—Immune system disorder—Methotrexate—esophageal cancer	0.000229	0.00142	CcSEcCtD
Octreotide—SSTR3—Signaling by GPCR—SST—esophageal cancer	0.000227	0.00158	CbGpPWpGaD
Octreotide—SSTR1—Signaling Pathways—CSNK1A1—esophageal cancer	0.000225	0.00157	CbGpPWpGaD
Octreotide—Diarrhoea—Cisplatin—esophageal cancer	0.000225	0.00139	CcSEcCtD
Octreotide—Alopecia—Methotrexate—esophageal cancer	0.000224	0.00139	CcSEcCtD
Octreotide—SSTR1—Signaling by GPCR—ANXA1—esophageal cancer	0.000223	0.00156	CbGpPWpGaD
Octreotide—SSTR2—Signaling by GPCR—GNG7—esophageal cancer	0.000223	0.00156	CbGpPWpGaD
Octreotide—Mental disorder—Methotrexate—esophageal cancer	0.000222	0.00137	CcSEcCtD
Octreotide—SSTR5—Signaling Pathways—FKBP1A—esophageal cancer	0.000222	0.00155	CbGpPWpGaD
Octreotide—SSTR4—Signaling Pathways—GNG7—esophageal cancer	0.000222	0.00155	CbGpPWpGaD
Octreotide—Malnutrition—Methotrexate—esophageal cancer	0.000221	0.00136	CcSEcCtD
Octreotide—Erythema—Methotrexate—esophageal cancer	0.000221	0.00136	CcSEcCtD
Octreotide—SSTR3—Signaling by GPCR—GHRL—esophageal cancer	0.000221	0.00154	CbGpPWpGaD
Octreotide—Musculoskeletal discomfort—Capecitabine—esophageal cancer	0.000221	0.00136	CcSEcCtD
Octreotide—SSTR3—Signaling Pathways—PFN1—esophageal cancer	0.00022	0.00154	CbGpPWpGaD
Octreotide—Insomnia—Capecitabine—esophageal cancer	0.000219	0.00135	CcSEcCtD
Octreotide—SSTR5—GPCR downstream signaling—ANXA1—esophageal cancer	0.000218	0.00152	CbGpPWpGaD
Octreotide—Paraesthesia—Capecitabine—esophageal cancer	0.000218	0.00134	CcSEcCtD
Octreotide—SSTR1—Signaling by GPCR—SST—esophageal cancer	0.000217	0.00152	CbGpPWpGaD
Octreotide—SSTR5—Signaling Pathways—WIF1—esophageal cancer	0.000217	0.00151	CbGpPWpGaD
Octreotide—SSTR2—GPCR downstream signaling—CXCL2—esophageal cancer	0.000217	0.00151	CbGpPWpGaD
Octreotide—Dyspnoea—Capecitabine—esophageal cancer	0.000216	0.00133	CcSEcCtD
Octreotide—SSTR2—Signaling Pathways—WWOX—esophageal cancer	0.000215	0.0015	CbGpPWpGaD
Octreotide—Back pain—Methotrexate—esophageal cancer	0.000214	0.00132	CcSEcCtD
Octreotide—Dyspepsia—Capecitabine—esophageal cancer	0.000213	0.00132	CcSEcCtD
Octreotide—SSTR5—Signaling by GPCR—CXCL2—esophageal cancer	0.000213	0.00149	CbGpPWpGaD
Octreotide—SSTR5—GPCR downstream signaling—SST—esophageal cancer	0.000212	0.00148	CbGpPWpGaD
Octreotide—SSTR1—Signaling by GPCR—GHRL—esophageal cancer	0.000212	0.00148	CbGpPWpGaD
Octreotide—SSTR1—Signaling Pathways—PFN1—esophageal cancer	0.000211	0.00147	CbGpPWpGaD
Octreotide—Decreased appetite—Capecitabine—esophageal cancer	0.000211	0.0013	CcSEcCtD
Octreotide—Gastrointestinal disorder—Capecitabine—esophageal cancer	0.000209	0.00129	CcSEcCtD
Octreotide—Vomiting—Cisplatin—esophageal cancer	0.000209	0.00129	CcSEcCtD
Octreotide—Fatigue—Capecitabine—esophageal cancer	0.000209	0.00129	CcSEcCtD
Octreotide—Vision blurred—Methotrexate—esophageal cancer	0.000208	0.00129	CcSEcCtD
Octreotide—SSTR4—Signaling Pathways—XIAP—esophageal cancer	0.000208	0.00145	CbGpPWpGaD
Octreotide—Rash—Cisplatin—esophageal cancer	0.000207	0.00128	CcSEcCtD
Octreotide—Pain—Capecitabine—esophageal cancer	0.000207	0.00128	CcSEcCtD
Octreotide—Constipation—Capecitabine—esophageal cancer	0.000207	0.00128	CcSEcCtD
Octreotide—Dermatitis—Cisplatin—esophageal cancer	0.000207	0.00128	CcSEcCtD
Octreotide—SSTR5—GPCR downstream signaling—GHRL—esophageal cancer	0.000207	0.00144	CbGpPWpGaD
Octreotide—Ill-defined disorder—Methotrexate—esophageal cancer	0.000205	0.00127	CcSEcCtD
Octreotide—SSTR2—Signaling Pathways—FKBP1A—esophageal cancer	0.000205	0.00143	CbGpPWpGaD
Octreotide—Anaemia—Methotrexate—esophageal cancer	0.000204	0.00126	CcSEcCtD
Octreotide—SSTR2—GPCR downstream signaling—ANXA1—esophageal cancer	0.000201	0.00141	CbGpPWpGaD
Octreotide—SSTR5—Signaling Pathways—CSNK1A1—esophageal cancer	0.0002	0.0014	CbGpPWpGaD
Octreotide—SSTR2—Signaling Pathways—WIF1—esophageal cancer	0.0002	0.0014	CbGpPWpGaD
Octreotide—Feeling abnormal—Capecitabine—esophageal cancer	0.0002	0.00123	CcSEcCtD
Octreotide—Malaise—Methotrexate—esophageal cancer	0.000199	0.00123	CcSEcCtD
Octreotide—Vertigo—Methotrexate—esophageal cancer	0.000199	0.00123	CcSEcCtD
Octreotide—Gastrointestinal pain—Capecitabine—esophageal cancer	0.000198	0.00122	CcSEcCtD
Octreotide—SSTR5—Signaling by GPCR—ANXA1—esophageal cancer	0.000198	0.00138	CbGpPWpGaD
Octreotide—SSTR3—Signaling Pathways—ELMO1—esophageal cancer	0.000198	0.00138	CbGpPWpGaD
Octreotide—SSTR2—Signaling by GPCR—CXCL2—esophageal cancer	0.000197	0.00137	CbGpPWpGaD
Octreotide—SSTR4—Signaling Pathways—CTNNA1—esophageal cancer	0.000196	0.00137	CbGpPWpGaD
Octreotide—SSTR2—GPCR downstream signaling—SST—esophageal cancer	0.000196	0.00137	CbGpPWpGaD
Octreotide—SSTR4—Signaling Pathways—CXCL2—esophageal cancer	0.000195	0.00136	CbGpPWpGaD
Octreotide—Nausea—Cisplatin—esophageal cancer	0.000195	0.00121	CcSEcCtD
Octreotide—SSTR3—Signaling Pathways—AKAP13—esophageal cancer	0.000193	0.00135	CbGpPWpGaD
Octreotide—Cough—Methotrexate—esophageal cancer	0.000193	0.00119	CcSEcCtD
Octreotide—SSTR5—Signaling by GPCR—SST—esophageal cancer	0.000193	0.00135	CbGpPWpGaD
Octreotide—Urticaria—Capecitabine—esophageal cancer	0.000193	0.00119	CcSEcCtD
Octreotide—Body temperature increased—Capecitabine—esophageal cancer	0.000192	0.00118	CcSEcCtD
Octreotide—Abdominal pain—Capecitabine—esophageal cancer	0.000192	0.00118	CcSEcCtD
Octreotide—Convulsion—Methotrexate—esophageal cancer	0.000192	0.00118	CcSEcCtD
Octreotide—SSTR2—GPCR downstream signaling—GHRL—esophageal cancer	0.000191	0.00133	CbGpPWpGaD
Octreotide—SSTR1—Signaling Pathways—ELMO1—esophageal cancer	0.000189	0.00132	CbGpPWpGaD
Octreotide—Myalgia—Methotrexate—esophageal cancer	0.000188	0.00116	CcSEcCtD
Octreotide—Arthralgia—Methotrexate—esophageal cancer	0.000188	0.00116	CcSEcCtD
Octreotide—Chest pain—Methotrexate—esophageal cancer	0.000188	0.00116	CcSEcCtD
Octreotide—SSTR5—Signaling by GPCR—GHRL—esophageal cancer	0.000188	0.00131	CbGpPWpGaD
Octreotide—SSTR5—Signaling Pathways—PFN1—esophageal cancer	0.000187	0.00131	CbGpPWpGaD
Octreotide—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—esophageal cancer	0.000187	0.00115	CcSEcCtD
Octreotide—Discomfort—Methotrexate—esophageal cancer	0.000186	0.00115	CcSEcCtD
Octreotide—SSTR1—Signaling Pathways—AKAP13—esophageal cancer	0.000185	0.00129	CbGpPWpGaD
Octreotide—SSTR2—Signaling Pathways—CSNK1A1—esophageal cancer	0.000185	0.00129	CbGpPWpGaD
Octreotide—SSTR2—Signaling by GPCR—ANXA1—esophageal cancer	0.000183	0.00128	CbGpPWpGaD
Octreotide—SSTR4—Signaling Pathways—PSME2—esophageal cancer	0.000182	0.00127	CbGpPWpGaD
Octreotide—SSTR4—Signaling Pathways—PSME1—esophageal cancer	0.000182	0.00127	CbGpPWpGaD
Octreotide—SSTR4—Signaling Pathways—ANXA1—esophageal cancer	0.000182	0.00127	CbGpPWpGaD
Octreotide—Anaphylactic shock—Methotrexate—esophageal cancer	0.00018	0.00111	CcSEcCtD
Octreotide—Infection—Methotrexate—esophageal cancer	0.000179	0.00111	CcSEcCtD
Octreotide—Hypersensitivity—Capecitabine—esophageal cancer	0.000179	0.0011	CcSEcCtD
Octreotide—SSTR3—Signaling Pathways—HIST1H2BM—esophageal cancer	0.000178	0.00124	CbGpPWpGaD
Octreotide—SSTR2—Signaling by GPCR—SST—esophageal cancer	0.000178	0.00124	CbGpPWpGaD
Octreotide—Nervous system disorder—Methotrexate—esophageal cancer	0.000177	0.00109	CcSEcCtD
Octreotide—Thrombocytopenia—Methotrexate—esophageal cancer	0.000177	0.00109	CcSEcCtD
Octreotide—SSTR4—Signaling Pathways—SST—esophageal cancer	0.000177	0.00123	CbGpPWpGaD
Octreotide—SSTR3—Signaling Pathways—PDE4D—esophageal cancer	0.000177	0.00123	CbGpPWpGaD
Octreotide—Skin disorder—Methotrexate—esophageal cancer	0.000175	0.00108	CcSEcCtD
Octreotide—Hyperhidrosis—Methotrexate—esophageal cancer	0.000174	0.00108	CcSEcCtD
Octreotide—Asthenia—Capecitabine—esophageal cancer	0.000174	0.00107	CcSEcCtD
Octreotide—SSTR2—Signaling by GPCR—GHRL—esophageal cancer	0.000173	0.00121	CbGpPWpGaD
Octreotide—SSTR2—Signaling Pathways—PFN1—esophageal cancer	0.000173	0.00121	CbGpPWpGaD
Octreotide—SSTR4—Signaling Pathways—NOTCH3—esophageal cancer	0.000172	0.0012	CbGpPWpGaD
Octreotide—SSTR4—Signaling Pathways—GHRL—esophageal cancer	0.000172	0.0012	CbGpPWpGaD
Octreotide—Anorexia—Methotrexate—esophageal cancer	0.000172	0.00106	CcSEcCtD
Octreotide—Pruritus—Capecitabine—esophageal cancer	0.000171	0.00106	CcSEcCtD
Octreotide—SSTR1—Signaling Pathways—HIST1H2BM—esophageal cancer	0.000171	0.00119	CbGpPWpGaD
Octreotide—SSTR4—Signaling Pathways—FBXW7—esophageal cancer	0.000169	0.00118	CbGpPWpGaD
Octreotide—SSTR1—Signaling Pathways—PDE4D—esophageal cancer	0.000169	0.00118	CbGpPWpGaD
Octreotide—SSTR5—Signaling Pathways—ELMO1—esophageal cancer	0.000168	0.00117	CbGpPWpGaD
Octreotide—SSTR3—Signaling Pathways—GNG7—esophageal cancer	0.000168	0.00117	CbGpPWpGaD
Octreotide—Diarrhoea—Capecitabine—esophageal cancer	0.000166	0.00102	CcSEcCtD
Octreotide—Musculoskeletal discomfort—Methotrexate—esophageal cancer	0.000164	0.00101	CcSEcCtD
Octreotide—SSTR5—Signaling Pathways—AKAP13—esophageal cancer	0.000164	0.00115	CbGpPWpGaD
Octreotide—Insomnia—Methotrexate—esophageal cancer	0.000163	0.00101	CcSEcCtD
Octreotide—Paraesthesia—Methotrexate—esophageal cancer	0.000162	0.001	CcSEcCtD
Octreotide—SSTR1—Signaling Pathways—GNG7—esophageal cancer	0.000161	0.00112	CbGpPWpGaD
Octreotide—Dyspnoea—Methotrexate—esophageal cancer	0.000161	0.000993	CcSEcCtD
Octreotide—Somnolence—Methotrexate—esophageal cancer	0.00016	0.00099	CcSEcCtD
Octreotide—Dizziness—Capecitabine—esophageal cancer	0.00016	0.000989	CcSEcCtD
Octreotide—Dyspepsia—Methotrexate—esophageal cancer	0.000159	0.00098	CcSEcCtD
Octreotide—SSTR3—Signaling Pathways—XIAP—esophageal cancer	0.000157	0.0011	CbGpPWpGaD
Octreotide—Decreased appetite—Methotrexate—esophageal cancer	0.000157	0.000968	CcSEcCtD
Octreotide—Gastrointestinal disorder—Methotrexate—esophageal cancer	0.000156	0.000961	CcSEcCtD
Octreotide—Fatigue—Methotrexate—esophageal cancer	0.000156	0.00096	CcSEcCtD
Octreotide—SSTR2—Signaling Pathways—ELMO1—esophageal cancer	0.000155	0.00108	CbGpPWpGaD
Octreotide—SSTR4—Signaling Pathways—NOTCH2—esophageal cancer	0.000154	0.00108	CbGpPWpGaD
Octreotide—Pain—Methotrexate—esophageal cancer	0.000154	0.000952	CcSEcCtD
Octreotide—Vomiting—Capecitabine—esophageal cancer	0.000154	0.000951	CcSEcCtD
Octreotide—Rash—Capecitabine—esophageal cancer	0.000153	0.000943	CcSEcCtD
Octreotide—Dermatitis—Capecitabine—esophageal cancer	0.000153	0.000942	CcSEcCtD
Octreotide—Headache—Capecitabine—esophageal cancer	0.000152	0.000937	CcSEcCtD
Octreotide—SSTR5—Signaling Pathways—HIST1H2BM—esophageal cancer	0.000152	0.00106	CbGpPWpGaD
Octreotide—SSTR2—Signaling Pathways—AKAP13—esophageal cancer	0.000152	0.00106	CbGpPWpGaD
Octreotide—SSTR1—Signaling Pathways—XIAP—esophageal cancer	0.000151	0.00105	CbGpPWpGaD
Octreotide—SSTR5—Signaling Pathways—PDE4D—esophageal cancer	0.00015	0.00105	CbGpPWpGaD
Octreotide—SSTR3—Signaling Pathways—CTNNA1—esophageal cancer	0.000149	0.00104	CbGpPWpGaD
Octreotide—Feeling abnormal—Methotrexate—esophageal cancer	0.000149	0.000918	CcSEcCtD
Octreotide—SSTR3—Signaling Pathways—CXCL2—esophageal cancer	0.000148	0.00103	CbGpPWpGaD
Octreotide—Gastrointestinal pain—Methotrexate—esophageal cancer	0.000148	0.000911	CcSEcCtD
Octreotide—Nausea—Capecitabine—esophageal cancer	0.000144	0.000889	CcSEcCtD
Octreotide—Urticaria—Methotrexate—esophageal cancer	0.000143	0.000885	CcSEcCtD
Octreotide—SSTR5—Signaling Pathways—GNG7—esophageal cancer	0.000143	0.000997	CbGpPWpGaD
Octreotide—SSTR1—Signaling Pathways—CTNNA1—esophageal cancer	0.000143	0.000996	CbGpPWpGaD
Octreotide—Body temperature increased—Methotrexate—esophageal cancer	0.000143	0.00088	CcSEcCtD
Octreotide—Abdominal pain—Methotrexate—esophageal cancer	0.000143	0.00088	CcSEcCtD
Octreotide—SSTR1—Signaling Pathways—CXCL2—esophageal cancer	0.000142	0.000991	CbGpPWpGaD
Octreotide—SSTR2—Signaling Pathways—HIST1H2BM—esophageal cancer	0.00014	0.000976	CbGpPWpGaD
Octreotide—SSTR2—Signaling Pathways—PDE4D—esophageal cancer	0.000139	0.000968	CbGpPWpGaD
Octreotide—SSTR3—Signaling Pathways—PSME1—esophageal cancer	0.000138	0.000965	CbGpPWpGaD
Octreotide—SSTR3—Signaling Pathways—PSME2—esophageal cancer	0.000138	0.000965	CbGpPWpGaD
Octreotide—SSTR3—Signaling Pathways—ANXA1—esophageal cancer	0.000138	0.000961	CbGpPWpGaD
Octreotide—SSTR4—Signaling Pathways—TGFBR2—esophageal cancer	0.000137	0.000956	CbGpPWpGaD
Octreotide—SSTR5—Signaling Pathways—XIAP—esophageal cancer	0.000134	0.000935	CbGpPWpGaD
Octreotide—SSTR3—Signaling Pathways—SST—esophageal cancer	0.000134	0.000935	CbGpPWpGaD
Octreotide—Hypersensitivity—Methotrexate—esophageal cancer	0.000133	0.00082	CcSEcCtD
Octreotide—SSTR1—Signaling Pathways—PSME1—esophageal cancer	0.000133	0.000925	CbGpPWpGaD
Octreotide—SSTR1—Signaling Pathways—PSME2—esophageal cancer	0.000133	0.000925	CbGpPWpGaD
Octreotide—SSTR1—Signaling Pathways—ANXA1—esophageal cancer	0.000132	0.000921	CbGpPWpGaD
Octreotide—SSTR2—Signaling Pathways—GNG7—esophageal cancer	0.000132	0.00092	CbGpPWpGaD
Octreotide—SSTR3—Signaling Pathways—NOTCH3—esophageal cancer	0.00013	0.000911	CbGpPWpGaD
Octreotide—SSTR3—Signaling Pathways—GHRL—esophageal cancer	0.00013	0.000911	CbGpPWpGaD
Octreotide—SSTR4—Signaling Pathways—SMAD4—esophageal cancer	0.00013	0.000905	CbGpPWpGaD
Octreotide—Asthenia—Methotrexate—esophageal cancer	0.000129	0.000799	CcSEcCtD
Octreotide—SSTR3—Signaling Pathways—FBXW7—esophageal cancer	0.000128	0.000896	CbGpPWpGaD
Octreotide—SSTR1—Signaling Pathways—SST—esophageal cancer	0.000128	0.000896	CbGpPWpGaD
Octreotide—Pruritus—Methotrexate—esophageal cancer	0.000128	0.000788	CcSEcCtD
Octreotide—SSTR5—Signaling Pathways—CTNNA1—esophageal cancer	0.000127	0.000884	CbGpPWpGaD
Octreotide—SSTR5—Signaling Pathways—CXCL2—esophageal cancer	0.000126	0.000879	CbGpPWpGaD
Octreotide—SSTR1—Signaling Pathways—GHRL—esophageal cancer	0.000125	0.000873	CbGpPWpGaD
Octreotide—SSTR1—Signaling Pathways—NOTCH3—esophageal cancer	0.000125	0.000873	CbGpPWpGaD
Octreotide—SSTR2—Signaling Pathways—XIAP—esophageal cancer	0.000124	0.000862	CbGpPWpGaD
Octreotide—Diarrhoea—Methotrexate—esophageal cancer	0.000123	0.000762	CcSEcCtD
Octreotide—SSTR1—Signaling Pathways—FBXW7—esophageal cancer	0.000123	0.000859	CbGpPWpGaD
Octreotide—Dizziness—Methotrexate—esophageal cancer	0.000119	0.000736	CcSEcCtD
Octreotide—SSTR5—Signaling Pathways—PSME2—esophageal cancer	0.000118	0.000821	CbGpPWpGaD
Octreotide—SSTR5—Signaling Pathways—PSME1—esophageal cancer	0.000118	0.000821	CbGpPWpGaD
Octreotide—SSTR5—Signaling Pathways—ANXA1—esophageal cancer	0.000117	0.000817	CbGpPWpGaD
Octreotide—SSTR3—Signaling Pathways—NOTCH2—esophageal cancer	0.000117	0.000817	CbGpPWpGaD
Octreotide—SSTR2—Signaling Pathways—CTNNA1—esophageal cancer	0.000117	0.000816	CbGpPWpGaD
Octreotide—SSTR2—Signaling Pathways—CXCL2—esophageal cancer	0.000116	0.000811	CbGpPWpGaD
Octreotide—Vomiting—Methotrexate—esophageal cancer	0.000115	0.000708	CcSEcCtD
Octreotide—SSTR5—Signaling Pathways—SST—esophageal cancer	0.000114	0.000795	CbGpPWpGaD
Octreotide—Rash—Methotrexate—esophageal cancer	0.000114	0.000702	CcSEcCtD
Octreotide—Dermatitis—Methotrexate—esophageal cancer	0.000114	0.000701	CcSEcCtD
Octreotide—Headache—Methotrexate—esophageal cancer	0.000113	0.000698	CcSEcCtD
Octreotide—SSTR1—Signaling Pathways—NOTCH2—esophageal cancer	0.000112	0.000783	CbGpPWpGaD
Octreotide—SSTR5—Signaling Pathways—GHRL—esophageal cancer	0.000111	0.000774	CbGpPWpGaD
Octreotide—SSTR5—Signaling Pathways—NOTCH3—esophageal cancer	0.000111	0.000774	CbGpPWpGaD
Octreotide—SSTR5—Signaling Pathways—FBXW7—esophageal cancer	0.000109	0.000762	CbGpPWpGaD
Octreotide—SSTR2—Signaling Pathways—PSME2—esophageal cancer	0.000108	0.000757	CbGpPWpGaD
Octreotide—SSTR2—Signaling Pathways—PSME1—esophageal cancer	0.000108	0.000757	CbGpPWpGaD
Octreotide—SSTR2—Signaling Pathways—ANXA1—esophageal cancer	0.000108	0.000754	CbGpPWpGaD
Octreotide—Nausea—Methotrexate—esophageal cancer	0.000107	0.000661	CcSEcCtD
Octreotide—SSTR4—Signaling Pathways—HIF1A—esophageal cancer	0.000106	0.000741	CbGpPWpGaD
Octreotide—SSTR2—Signaling Pathways—SST—esophageal cancer	0.000105	0.000733	CbGpPWpGaD
Octreotide—SSTR3—Signaling Pathways—TGFBR2—esophageal cancer	0.000104	0.000725	CbGpPWpGaD
Octreotide—SSTR2—Signaling Pathways—NOTCH3—esophageal cancer	0.000102	0.000715	CbGpPWpGaD
Octreotide—SSTR2—Signaling Pathways—GHRL—esophageal cancer	0.000102	0.000715	CbGpPWpGaD
Octreotide—SSTR4—Signaling Pathways—KDR—esophageal cancer	0.000101	0.000708	CbGpPWpGaD
Octreotide—SSTR2—Signaling Pathways—FBXW7—esophageal cancer	0.000101	0.000703	CbGpPWpGaD
Octreotide—SSTR1—Signaling Pathways—TGFBR2—esophageal cancer	9.95e-05	0.000695	CbGpPWpGaD
Octreotide—SSTR5—Signaling Pathways—NOTCH2—esophageal cancer	9.95e-05	0.000695	CbGpPWpGaD
Octreotide—SSTR3—Signaling Pathways—SMAD4—esophageal cancer	9.82e-05	0.000686	CbGpPWpGaD
Octreotide—SSTR4—Signaling Pathways—NOTCH1—esophageal cancer	9.56e-05	0.000667	CbGpPWpGaD
Octreotide—SSTR1—Signaling Pathways—SMAD4—esophageal cancer	9.42e-05	0.000658	CbGpPWpGaD
Octreotide—SSTR2—Signaling Pathways—NOTCH2—esophageal cancer	9.18e-05	0.000641	CbGpPWpGaD
Octreotide—SSTR5—Signaling Pathways—TGFBR2—esophageal cancer	8.83e-05	0.000616	CbGpPWpGaD
Octreotide—SSTR4—Signaling Pathways—CREBBP—esophageal cancer	8.66e-05	0.000605	CbGpPWpGaD
Octreotide—SSTR4—Signaling by GPCR—EGFR—esophageal cancer	8.51e-05	0.000594	CbGpPWpGaD
Octreotide—SSTR5—Signaling Pathways—SMAD4—esophageal cancer	8.35e-05	0.000583	CbGpPWpGaD
Octreotide—SSTR2—Signaling Pathways—TGFBR2—esophageal cancer	8.14e-05	0.000569	CbGpPWpGaD
Octreotide—SSTR4—GPCR downstream signaling—PIK3CA—esophageal cancer	8.14e-05	0.000568	CbGpPWpGaD
Octreotide—SSTR3—Signaling Pathways—HIF1A—esophageal cancer	8.04e-05	0.000561	CbGpPWpGaD
Octreotide—SSTR4—Signaling Pathways—NOS3—esophageal cancer	7.76e-05	0.000542	CbGpPWpGaD
Octreotide—SSTR2—Signaling Pathways—SMAD4—esophageal cancer	7.71e-05	0.000538	CbGpPWpGaD
Octreotide—SSTR1—Signaling Pathways—HIF1A—esophageal cancer	7.71e-05	0.000538	CbGpPWpGaD
Octreotide—SSTR3—Signaling Pathways—KDR—esophageal cancer	7.69e-05	0.000537	CbGpPWpGaD
Octreotide—SSTR4—Signaling by GPCR—PIK3CA—esophageal cancer	7.39e-05	0.000516	CbGpPWpGaD
Octreotide—SSTR1—Signaling Pathways—KDR—esophageal cancer	7.37e-05	0.000515	CbGpPWpGaD
Octreotide—SSTR4—Signaling Pathways—ERBB2—esophageal cancer	7.26e-05	0.000507	CbGpPWpGaD
Octreotide—SSTR3—Signaling Pathways—NOTCH1—esophageal cancer	7.24e-05	0.000506	CbGpPWpGaD
Octreotide—SSTR1—Signaling Pathways—NOTCH1—esophageal cancer	6.94e-05	0.000485	CbGpPWpGaD
Octreotide—SSTR5—Signaling Pathways—HIF1A—esophageal cancer	6.84e-05	0.000477	CbGpPWpGaD
Octreotide—SSTR3—Signaling Pathways—CREBBP—esophageal cancer	6.57e-05	0.000458	CbGpPWpGaD
Octreotide—SSTR5—Signaling Pathways—KDR—esophageal cancer	6.54e-05	0.000456	CbGpPWpGaD
Octreotide—SSTR3—Signaling by GPCR—EGFR—esophageal cancer	6.45e-05	0.00045	CbGpPWpGaD
Octreotide—SSTR4—Signaling Pathways—CCND1—esophageal cancer	6.41e-05	0.000448	CbGpPWpGaD
Octreotide—SSTR2—Signaling Pathways—HIF1A—esophageal cancer	6.31e-05	0.00044	CbGpPWpGaD
Octreotide—SSTR1—Signaling Pathways—CREBBP—esophageal cancer	6.3e-05	0.00044	CbGpPWpGaD
Octreotide—SSTR4—Signaling Pathways—CDKN1A—esophageal cancer	6.2e-05	0.000433	CbGpPWpGaD
Octreotide—SSTR1—Signaling by GPCR—EGFR—esophageal cancer	6.19e-05	0.000432	CbGpPWpGaD
Octreotide—SSTR3—GPCR downstream signaling—PIK3CA—esophageal cancer	6.17e-05	0.000431	CbGpPWpGaD
Octreotide—SSTR5—Signaling Pathways—NOTCH1—esophageal cancer	6.16e-05	0.00043	CbGpPWpGaD
Octreotide—SSTR2—Signaling Pathways—KDR—esophageal cancer	6.03e-05	0.000421	CbGpPWpGaD
Octreotide—SSTR1—GPCR downstream signaling—PIK3CA—esophageal cancer	5.91e-05	0.000413	CbGpPWpGaD
Octreotide—SSTR4—Signaling Pathways—EP300—esophageal cancer	5.9e-05	0.000412	CbGpPWpGaD
Octreotide—SSTR3—Signaling Pathways—NOS3—esophageal cancer	5.88e-05	0.00041	CbGpPWpGaD
Octreotide—SSTR2—Signaling Pathways—NOTCH1—esophageal cancer	5.68e-05	0.000397	CbGpPWpGaD
Octreotide—SSTR1—Signaling Pathways—NOS3—esophageal cancer	5.64e-05	0.000394	CbGpPWpGaD
Octreotide—SSTR3—Signaling by GPCR—PIK3CA—esophageal cancer	5.6e-05	0.000391	CbGpPWpGaD
Octreotide—SSTR5—Signaling Pathways—CREBBP—esophageal cancer	5.58e-05	0.00039	CbGpPWpGaD
Octreotide—SSTR3—Signaling Pathways—ERBB2—esophageal cancer	5.5e-05	0.000384	CbGpPWpGaD
Octreotide—SSTR5—Signaling by GPCR—EGFR—esophageal cancer	5.49e-05	0.000383	CbGpPWpGaD
Octreotide—SSTR1—Signaling by GPCR—PIK3CA—esophageal cancer	5.37e-05	0.000375	CbGpPWpGaD
Octreotide—SSTR1—Signaling Pathways—ERBB2—esophageal cancer	5.27e-05	0.000368	CbGpPWpGaD
Octreotide—SSTR5—GPCR downstream signaling—PIK3CA—esophageal cancer	5.24e-05	0.000366	CbGpPWpGaD
Octreotide—SSTR2—Signaling Pathways—CREBBP—esophageal cancer	5.15e-05	0.00036	CbGpPWpGaD
Octreotide—SSTR4—Signaling Pathways—MYC—esophageal cancer	5.14e-05	0.000359	CbGpPWpGaD
Octreotide—SSTR2—Signaling by GPCR—EGFR—esophageal cancer	5.06e-05	0.000354	CbGpPWpGaD
Octreotide—SSTR4—Signaling Pathways—EGFR—esophageal cancer	5.03e-05	0.000351	CbGpPWpGaD
Octreotide—SSTR5—Signaling Pathways—NOS3—esophageal cancer	5e-05	0.000349	CbGpPWpGaD
Octreotide—SSTR3—Signaling Pathways—CCND1—esophageal cancer	4.86e-05	0.000339	CbGpPWpGaD
Octreotide—SSTR2—GPCR downstream signaling—PIK3CA—esophageal cancer	4.84e-05	0.000338	CbGpPWpGaD
Octreotide—SSTR5—Signaling by GPCR—PIK3CA—esophageal cancer	4.76e-05	0.000332	CbGpPWpGaD
Octreotide—SSTR3—Signaling Pathways—CDKN1A—esophageal cancer	4.7e-05	0.000328	CbGpPWpGaD
Octreotide—SSTR5—Signaling Pathways—ERBB2—esophageal cancer	4.68e-05	0.000326	CbGpPWpGaD
Octreotide—SSTR1—Signaling Pathways—CCND1—esophageal cancer	4.66e-05	0.000325	CbGpPWpGaD
Octreotide—SSTR2—Signaling Pathways—NOS3—esophageal cancer	4.61e-05	0.000322	CbGpPWpGaD
Octreotide—SSTR1—Signaling Pathways—CDKN1A—esophageal cancer	4.51e-05	0.000315	CbGpPWpGaD
Octreotide—SSTR3—Signaling Pathways—EP300—esophageal cancer	4.47e-05	0.000312	CbGpPWpGaD
Octreotide—SSTR2—Signaling by GPCR—PIK3CA—esophageal cancer	4.39e-05	0.000307	CbGpPWpGaD
Octreotide—SSTR4—Signaling Pathways—PIK3CA—esophageal cancer	4.37e-05	0.000305	CbGpPWpGaD
Octreotide—SSTR2—Signaling Pathways—ERBB2—esophageal cancer	4.32e-05	0.000301	CbGpPWpGaD
Octreotide—SSTR1—Signaling Pathways—EP300—esophageal cancer	4.29e-05	0.000299	CbGpPWpGaD
Octreotide—SSTR4—Signaling Pathways—TP53—esophageal cancer	4.22e-05	0.000295	CbGpPWpGaD
Octreotide—SSTR5—Signaling Pathways—CCND1—esophageal cancer	4.13e-05	0.000288	CbGpPWpGaD
Octreotide—SSTR5—Signaling Pathways—CDKN1A—esophageal cancer	4e-05	0.000279	CbGpPWpGaD
Octreotide—SSTR3—Signaling Pathways—MYC—esophageal cancer	3.9e-05	0.000272	CbGpPWpGaD
Octreotide—SSTR2—Signaling Pathways—CCND1—esophageal cancer	3.81e-05	0.000266	CbGpPWpGaD
Octreotide—SSTR3—Signaling Pathways—EGFR—esophageal cancer	3.81e-05	0.000266	CbGpPWpGaD
Octreotide—SSTR5—Signaling Pathways—EP300—esophageal cancer	3.8e-05	0.000265	CbGpPWpGaD
Octreotide—SSTR1—Signaling Pathways—MYC—esophageal cancer	3.74e-05	0.000261	CbGpPWpGaD
Octreotide—SSTR2—Signaling Pathways—CDKN1A—esophageal cancer	3.69e-05	0.000257	CbGpPWpGaD
Octreotide—SSTR1—Signaling Pathways—EGFR—esophageal cancer	3.65e-05	0.000255	CbGpPWpGaD
Octreotide—SSTR2—Signaling Pathways—EP300—esophageal cancer	3.51e-05	0.000245	CbGpPWpGaD
Octreotide—SSTR5—Signaling Pathways—MYC—esophageal cancer	3.31e-05	0.000231	CbGpPWpGaD
Octreotide—SSTR3—Signaling Pathways—PIK3CA—esophageal cancer	3.31e-05	0.000231	CbGpPWpGaD
Octreotide—SSTR5—Signaling Pathways—EGFR—esophageal cancer	3.24e-05	0.000226	CbGpPWpGaD
Octreotide—SSTR3—Signaling Pathways—TP53—esophageal cancer	3.2e-05	0.000223	CbGpPWpGaD
Octreotide—SSTR1—Signaling Pathways—PIK3CA—esophageal cancer	3.17e-05	0.000221	CbGpPWpGaD
Octreotide—SSTR1—Signaling Pathways—TP53—esophageal cancer	3.07e-05	0.000214	CbGpPWpGaD
Octreotide—SSTR2—Signaling Pathways—MYC—esophageal cancer	3.06e-05	0.000214	CbGpPWpGaD
Octreotide—SSTR2—Signaling Pathways—EGFR—esophageal cancer	2.99e-05	0.000209	CbGpPWpGaD
Octreotide—SSTR5—Signaling Pathways—PIK3CA—esophageal cancer	2.81e-05	0.000196	CbGpPWpGaD
Octreotide—SSTR5—Signaling Pathways—TP53—esophageal cancer	2.72e-05	0.00019	CbGpPWpGaD
Octreotide—SSTR2—Signaling Pathways—PIK3CA—esophageal cancer	2.6e-05	0.000181	CbGpPWpGaD
Octreotide—SSTR2—Signaling Pathways—TP53—esophageal cancer	2.51e-05	0.000175	CbGpPWpGaD
